Cost‐effective identification of Barrett's esophagus in the community: A first step towards screening
Journal of Gastroenterology and Hepatology · 2024
DOI: 10.1111/jgh.16762 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Tomonori Aoki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Barrett Esophagus, Cost-Benefit Analysis, Mass Screening. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: APAGE/JGH Foundation Clinician-Scientist Training Fellowship, Cancer Council South Australia Beat Cancer Early Career Research Fellowship.
Abstract (Originalsprache)
Background and Aim The first step towards developing a screening strategy for Barrett's esophagus (BE) is the identification of individuals in the community. Currently available tools include endoscopy, less‐invasive non‐endoscopic devices, and non‐invasive risk stratification models. We evaluated the cost of potential strategies for identification of BE as a first step towards screening.
Methods
Two hypothetical cohorts of the general population aged ≥ 50 years with BE prevalence rates of 1.9% and 6.8% were modeled. Four potential screening tools were evaluated: (i) risk stratification based on non‐weighted clinical factors according to US/European guidelines, (ii) weighted risk stratification using algorithmic models, (iii) less‐invasive devices such as Cytosponge + trefoil factor 3 (TFF3), and (iv) endoscopy. Using a decision‐analytic model, the cost per BE case identified and the cost‐effectiveness were compared for six potential BE screening strategies based on combinations of the four screening tools; (i) + (iv), (ii) + (iv), (iii) + (iv), (i) + (iii) + (iv), (ii) + (iii) + (iv), and only (iv).
Results
The cost per BE case identified was lowest for the weighted risk stratification followed by Cytosponge‐TFF3 then endoscopy strategy at both 1.9% and 6.8% BE prevalences (US$9282 and US$3406, respectively) although it was sensitive to the cost of less‐invasive devices. This strategy was also most cost‐effective for a BE prevalence of 1.9%. At BE prevalence of 6.8%, the Cytosponge‐TFF3 followed by endoscopy strategy was most cost‐effective.
Conclusions
Incorporating weighted risk stratification and less‐invasive devices such as Cytosponge‐TFF3 into BE screening strategies has a potential to cost‐effectively identify BE in the community although device cost and the community prevalence of BE will impact the optimal strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
- Department of Surgery, Flinders Medical Centre, Adelaide, South Australia, Australia.
ORCID-Profile: Tomonori Aoki
Förderung
- APAGE/JGH Foundation Clinician-Scientist Training Fellowship
- Cancer Council South Australia Beat Cancer Early Career Research Fellowship
Zitieren
APA
Aoki, T., Watson, D. I., & Bulamu, N. B. (2024). Cost‐effective identification of Barrett's esophagus in the community: A first step towards screening. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16762
Vancouver
Aoki T, Watson DI, Bulamu NB. Cost‐effective identification of Barrett's esophagus in the community: A first step towards screening. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16762
BibTeX
@article{Aoki2024,
author = {Aoki, Tomonori and Watson, David I and Bulamu, Norma B},
title = {Cost‐effective identification of Barrett's esophagus in the community: A first step towards screening},
journal = {Journal of Gastroenterology and Hepatology},
year = {2024},
doi = {10.1111/jgh.16762}
}
EUVIMED